论文部分内容阅读
目的探讨放化疗联合CIK细胞治疗晚期呼吸系统肿瘤的疗效。方法将101例患者随机分为免疫组和放化疗组。分离免疫组外周血单个核细胞(PBMC),体外诱导培养成CIK细胞后经静脉回输。患者均获随访,时间2～48个月,定期复查免疫指标及临床症状。结果与放化疗组比较,免疫组免疫指标除CD3+T外均增高(P<0.05),体重、KPS评分及生存率得到改善(P<0.01),CEA和VAS评价值降低(P<0.01)。结论放化疗联合CIK细胞免疫治疗能够改善晚期呼吸系统肿瘤患者免疫功能和生活质量,延长生存期。
Objective To investigate the curative effect of radiotherapy and chemotherapy combined with CIK cells in the treatment of advanced respiratory system tumors. Methods 101 patients were randomly divided into immune group and radiotherapy and chemotherapy group. Peripheral blood mononuclear cells (PBMCs) were isolated from immunized group and were transplanted intravenously after induction of CIK cells in vitro. Patients were followed up for 2 ~ 48 months, regular review of immune indicators and clinical symptoms. Results Compared with the radiotherapy and chemotherapy group, the immunological indexes of immunized group were higher than that of CD3 + T group (P <0.05), the weight, KPS score and survival rate were improved (P <0.01), CEA and VAS values were lower . Conclusions Radiotherapy combined with CIK cell immunotherapy can improve immune function and quality of life in patients with advanced respiratory system cancer and prolong survival.